Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: a double-blind randomised controlled trial.
COMPLEMENTARY MEDICINE
COVID-19
Clinical Trial
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
22 09 2023
22 09 2023
Historique:
medline:
25
9
2023
pubmed:
23
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
COVID-19 has caused morbidity, hospitalisation and mortality worldwide. Despite effective vaccines, there is still a need for effective treatments, especially for people in the community. Dietary supplements have long been used to treat respiratory infections, and preliminary evidence indicates some may be effective in people with COVID-19. We sought to evaluate whether a combination of vitamin C, vitamin D Participants were randomised to receive either vitamin C (6 g), vitamin D 90 patients (46 control, 44 treatment) were randomised. The study was stopped prematurely due to insufficient capacity for recruitment. The mean difference (control-treatment) in cumulative overall health was -37.4 (95% CI -157.2 to 82.3), p=0.53 on a scale of 0-2100. No clinically or statistically significant differences were seen in any secondary outcomes. In this double-blind, placebo-controlled, randomised trial of outpatients diagnosed with COVID-19, the dietary supplements vitamin C, vitamin D NCT04780061.
Sections du résumé
BACKGROUND
COVID-19 has caused morbidity, hospitalisation and mortality worldwide. Despite effective vaccines, there is still a need for effective treatments, especially for people in the community. Dietary supplements have long been used to treat respiratory infections, and preliminary evidence indicates some may be effective in people with COVID-19. We sought to evaluate whether a combination of vitamin C, vitamin D
METHODS
Participants were randomised to receive either vitamin C (6 g), vitamin D
RESULTS
90 patients (46 control, 44 treatment) were randomised. The study was stopped prematurely due to insufficient capacity for recruitment. The mean difference (control-treatment) in cumulative overall health was -37.4 (95% CI -157.2 to 82.3), p=0.53 on a scale of 0-2100. No clinically or statistically significant differences were seen in any secondary outcomes.
INTERPRETATION
In this double-blind, placebo-controlled, randomised trial of outpatients diagnosed with COVID-19, the dietary supplements vitamin C, vitamin D
TRIAL REGISTRATION NUMBER
NCT04780061.
Identifiants
pubmed: 37739466
pii: bmjopen-2023-073761
doi: 10.1136/bmjopen-2023-073761
pmc: PMC10533655
doi:
Substances chimiques
Zinc Acetate
FM5526K07A
Vitamins
0
Ascorbic Acid
PQ6CK8PD0R
Cholecalciferol
1C6V77QF41
Vitamin K 2
11032-49-8
Banques de données
ClinicalTrials.gov
['NCT04780061']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e073761Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Nutrients. 2017 Mar 29;9(4):
pubmed: 28353648
J Public Health Manag Pract. 2021 May-Jun 01;27(3):246-250
pubmed: 33729203
Antimicrob Agents Chemother. 1987 Apr;31(4):622-4
pubmed: 3038000
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Organization (Lond). 2023 Jan;30(1):193-209
pubmed: 37038431
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
CMAJ. 2012 Jul 10;184(10):E551-61
pubmed: 22566526
JAMA. 2022 Aug 16;328(7):611
pubmed: 35972478
PLoS One. 2017 Aug 4;12(8):e0181780
pubmed: 28783743
Front Immunol. 2020 Jul 21;11:1817
pubmed: 32793245
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Open Forum Infect Dis. 2021 Jul 29;8(10):ofab408
pubmed: 34642636
Value Health. 2019 Jan;22(1):23-30
pubmed: 30661630
Pharmacol Res. 2010 Sep;62(3):237-42
pubmed: 20478383
JAMA Netw Open. 2021 Feb 1;4(2):e210369
pubmed: 33576820
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD000980
pubmed: 15495002
Risk Manag Healthc Policy. 2021 Jan 07;14:31-38
pubmed: 33447107
Med Hypotheses. 1996 Mar;46(3):295-302
pubmed: 8676770
Clin Infect Dis. 2021 Dec 6;73(11):e4039-e4046
pubmed: 32852539
Qual Life Res. 2014 Apr;23(3):977-89
pubmed: 24081873
BMJ Open. 2022 Mar 3;12(3):e057024
pubmed: 35241474
Int J Environ Res Public Health. 2018 Sep 14;15(9):
pubmed: 30223447
Microbes Infect. 2017 Dec;19(12):605-615
pubmed: 28889969
J Virol. 1976 Apr;18(1):298-306
pubmed: 176466
Front Immunol. 2021 Oct 11;12:714170
pubmed: 34707602
BMJ. 2017 Feb 15;356:i6583
pubmed: 28202713
BMJ. 2022 Aug 2;378:o1806
pubmed: 35918084
Lancet Respir Med. 2021 Dec;9(12):1450-1466
pubmed: 34688434
J Nutr Health Aging. 2018;22(4):491-500
pubmed: 29582888
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238